All posts related to "biologics"

Deep Cove teen on systemic juvenile idiopathic arthritis

Picture of Senya Kyle who lives with systemic juvenile idiopathic arthritis

Picture from North Shore News: http://www.nsnews.com/lifestyle/deep-cove-teen-has-cautionary-health-tale-1.23127827

Deep Cove resident Senya Kyle has lived with chronic pain from systemic juvenile idiopathic arthritis (sJIA) since she was a little girl. Senya is now a Grade 10 student at Seycove secondary. Instead of playing soccer and hiking Quarry Rock with her friends and participating in other school activities, she watches from the sidelines. After school, she can’t even join her friends for a walk around the mall.

Due to her sJIA, Senya has fused vertebrae in her neck, along with serious joint damage in her feet. As of yesterday, the number of ankle surgery Senya has gone through is four. According to Senya, every step she takes is a dull ache mixed with stabbing pain in her ankle. Sometimes, her pain is so unbearable that she cannot move. She is forced to live a sedentary life at the young age of 15. In an interview with North Shore News, Senya says: “That’s pretty much all I can do, is sit down and hope that (the pain) will go away.” At her worst, Senya had 40 joints inflamed at one time.

Continue reading

Biologic Use During Pregnancy May Not Increase Infection Risks in Infants

ACE has carefully monitored the research on biologic use during pregnancy in response to the many ACE members who are thinking of starting a family and have concerns about continuing their medications.

We have previously reported on the study by Dr. Mary De Vera, Assistant Professor at the University of British Columbia’s Faculty of Pharmaceutical Sciences, and her team on “Patterns of medication use before, during, and after pregnancy among women with systemic lupus erythematosus: A population-based study”.

picture of pregnant womanDr. De Vera’s team assessed the use of medications in pregnant women with lupus in British Columbia. Most pregnancy trimesters in the study were exposed to hydroxychloroquine and/or chloroquine (41 to 45% of exposed pregnancy trimesters). The research observed an increase in glucocorticosteroid (like prednisone) exposures during pregnancy, as well as post-delivery. Findings emphasized the importance of counseling women regarding childbearing decisions as well as the need for evaluation of the risk-benefit profiles of medications in pregnancy.
Continue reading

Have you signed up yet?

Have you recently been recommended to START or SWITCH biologic medications for rheumatoid arthritis?

SuPER study bannerWe are looking for people with rheumatoid arthritis across Canada to test a new online tool that helps to make decisions about using biologic medications.

If you have been recommended to consider STARTING or SWITCHING biologics, we invite you to participate in this study.

You may be eligible if you:

  1. Have rheumatoid arthritis
  2. See a rheumatologist
  3. You are considering or reconsidering starting or switching biologics
  4. Have a valid email and internet access

This study can be completed from home or anywhere with internet access. Any information you provide will be completely confidential. An honorarium will be provided for your time.

If you would like more information, please contact Jasmina Memetovic, Research Coordinator by phone at 604-207-4007, toll free 1-877-871-4575, or email jmemetovic@arthritisresearch.ca.

Life-changing biologics: So close, yet so far

A person with a graduate hat and gownOliver Sachgau, a young university graduate living with juvenile arthritis, shared his medication treatment journey with the Globe and Mail this week. He was diagnosed with juvenile arthritis at the young age of 14. Throughout his high school and university years, he kept his arthritis symptom-free by taking the biologics Enbrel, which costs $1,800 a month and was thankfully covered under his family’s insurance plan.  When he graduated from university, he was no longer covered under his family’s health plan.

In the article, he said: “I’m not a unique case. Enbrel is part of a class of medication called biologics. For those who take them, biologics can perform miracles. But their high cost, which is rarely mitigated by medical coverage, has created a unique situation for thousands of Canadians who want, but can’t have, their life-changing medication.” The medication cost Canada’s public health plans more than half a billion dollars in 2013, for about 30,000 beneficiaries. Continue reading

Do you have rheumatoid arthritis? This study is for you!

Online ToolDo you have rheumatoid arthritis and have you recently been recommended to START or SWITCH biologic medications?

Researchers at Arthritis Research Canada would like YOU to try the latest online tool to help make your treatment decisions. 

We are looking for people with rheumatoid arthritis across Canada to try a new online tool that helps to make decisions about using biologic medications.

If you have been recommended to consider starting or switching biologic medications, we invite you to participate in this study. You may be eligible if you:

  1. Have rheumatoid arthritis
  2. See a rheumatologist
  3. You are considering or reconsidering starting or switching biologics
  4. Have a valid email and internet access

We are more than halfway there! We now have 28 participants who have completed the study. Please help us reach our recruitment target of 55 participants.

The study will take about two hours to complete over a span of four to six weeks, and can be completed remotely.  Any information you provide will be completely confidential. An honorarium will be provided for your time.

If you would like more information, please contact Jasmina Memetovic, Research Coordinator by phone at 604-207-4007, toll free 1-877-871-4575, or email jmemetovic@arthritisresearch.ca.

FDA proposed new naming policies for biosimilar drugs for RA

Yellow and Purple pills in palm of handThe Food and Drug Administration (FDA) has proposed new naming policies for the distinct naming of biosimilars and biologics for rheumatoid arthritis treatment. The new draft guidance is called Nonproprietary Naming of Biological Products: Guidance for Industry and is available to view here.

Under the new policies, which will be designated and enforced by the FDA, separate and distinctive names will be required when it comes to biosimilars and biologic drugs. This will ensure that pharmaceutical companies are following regulations and will remain compliant when it comes to the naming and marketing of biosimilar medications.  Continue reading

ACE asks Canadians: How does your province measure up?

ARTHRITIS CONSUMER EXPERTS ASKS CANADIANS: HOW DOES YOUR PROVINCE MEASURE UP?

ACE’s Arthritis Medications Report Card helps Canadians evaluate reimbursement access to arthritis medications 

(Vancouver, BC) — In its eighth annual JointHealth™ Arthritis Medications Report Card, Arthritis Consumer Experts (ACE) reports that, depending on where they live, Canadians living with an autoimmune arthritis may have fewer treatment options or have to “jump through more hoops” to qualify for reimbursement for the medication prescribed for them by their rheumatologist.

“ACE continues to fight for the rights of people with arthritis, which includes our leadership on timely and equitable reimbursement access to arthritis medications on public and private drug formularies. Studies have found that increases in medication treatment costs for rheumatoid arthritis over the last decade are associated with lower hospitalization rates, better functional status and a lower incidence of work disability,” said Cheryl Koehn, Founder and President of Arthritis Consumer Experts.

JointHealth Report Card Segment Continue reading

Have you recently been recommended to take BIOLOGIC medications for Rheumatoid Arthritis?

the news

Image courtesy of hywards at FreeDigitalPhotos.net

Have you recently been recommended to take BIOLOGIC medications for Rheumatoid Arthritis? 

The latest online tool to help make your treatment decisions.

We are looking for people with rheumatoid arthritis to test a new online tool that helps to make decisions about using biologic medications.

If you have been recommended to consider using a biologic by your doctor but have not started yet, we invite you to participate in this study.

You may be eligible if you:

  1. Have rheumatoid arthritis
  2. See a rheumatologist
  3. Have received a recommendation to consider biologic therapy
  4. Have a valid email and internet access

The study will take about two hours to complete over a span of four to six weeks, and can be completed remotely. Any information you provide will be completely confidential. An honorarium will be provided for your time.

If you would like more information, please contact Jasmina Memetovic, Research Coordinator by phone at 604-207-4007, toll free 1-877-871-4575, or email jmemetovic@arthritisresearch.ca.

The results are in for psoriatic arthritis & psoriasis survey

MAPPThe Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey confirms psoriasis and psoriatic arthritis (PsA) are frequently under treated or not treated at all. MAPP is the first probability survey that looked at patients, regardless of whether they were under the care of a healthcare provider or member of a patient advocacy group, and also included the physician perspective. The survey interviewed 3,426 patients who were randomly selected via a telephone survey of 139,948 households in the United States, Canada, France, Germany, Italy, Spain, and the United Kingdom. It also interviewed a total of 781 physicians from North America and Europe. The survey explored the following: Continue reading

Arthritis Consumer Experts (ACE) at the 2014 CADTH Symposium

Snow over QuebecCheryl Koehn, President of Arthritis Consumer Experts (ACE), spoke in today’s session at the 2014 CADTH Symposium held at the Hilton Lac-Leamy, Gaitneu, Quebec. The 2014 CADTH Symposium is the tenth pan-Canadian forum organized by the Canadian Agency for Drugs and Technologies in Health for producers and users of evidenced-based information on drugs and other health technologies in Canada. This year’s Symposium is titled The Realities of Health Care Decision-Making: Evidence, Values, and Collaboration and comprises of 3 plenary sessions, 22 panel discussions, 9 oral sessions, 13 workshops and more than 40 scientific posters – all helping to enhance decision-making, reduce uncertainty, improve health outcomes and increase the value and sustainability of health care in Canada and around the world.

ACE is proud to be a part of the Symposium. Cheryl was one of the panellists today at “Session D2 – Panel Discussion: Health Technology Assessment of Biosimiliars (Subsequent Entry Biologics): A Canadian Perspective.” She spoke alongside the following panellists: Continue reading